Market Movers: Resmed Soars, Royal Caribbean and Alnylam Shine

1. Resmed (NYSE: RMD)
Resmed surged by 7.31%. ResMed reported several insider transactions throughout August 2024, with significant share sales by executives, including 14,700 shares by CEO Farrell Michael J. RBC Capital updated ResMed's price target to $206.00 while maintaining a Sector Perform rating, and KeyBanc set a target of $251.00.

2. Royal Caribbean Cruises Ltd. (NYSE: RCL)
Royal Caribbean Cruises Ltd. gained solidly by 4.33%. Royal Caribbean Cruises' Q2 2024 revenue was $7.838 billion, up 22.32% YoY. On August 19, Director Sorensen Vagn O sold 5,800 shares. Morgan Stanley maintained an Equal-Weight rating with a $154 target. Tigress Financial maintained a Buy rating with a $210 target.

3. Alnylam Pharmaceuticals (Nasdaq: ALNY)
Alnylam Pharmaceuticals gained solidly by 4.13%. Alnylam Pharmaceuticals reported H1 2024 revenue of $1.54 billion, up 80.89 percent year-over-year, with a net loss of $82.82 million. JP Morgan maintains a Neutral rating with a $280.00 target, HC Wainwright a Buy with a $400.00 target, and Goldman Sachs a Buy with a $370.00 target.

4. Gsk Plc (NYSE: GSK)
Gsk Plc gained solidly by 3.97%. GlaxoSmithKline (GSK) received approval for a new clinical trial of belimumab injection in China for CTD-ILD. Additionally, GSK and its joint venture ViiV Healthcare launched the second phase of an HIV ongoing care initiative with the Chinese Association of STD & AIDS Prevention. GSK also initiated a Phase 2 trial of dostarlimab for locally advanced rectal cancer in China.

5. Monolithic Power Systems (Nasdaq: MPWR)
Monolithic Power Systems gained solidly by 3.64%. Monolithic Power disclosed several insider transactions in August, including sales by executives Xiao Deming and Hsing Michael. The company released its mid-year report on August 2, showing $965 million in revenue. TD Cowen, Needham, and Raymond James maintained their buy ratings with target prices of $1100, $1000, and $925 respectively.